MedTrace Logo

Drug Interaction Study - Effect of AZD5672 on the Pharmacokinetics of Digoxin

NCT00723424 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2010-12-02

No results posted yet for this study

Summary

The purpose of the study is to examine the effect of AZD5672 (dosed to steady state) on the pharmacokinetics of digoxin (single dose administration).

Conditions

  • Healthy Volunteers
  • Pharmacokinetics

Interventions

DRUG

AZD5672

50 mg, for 13 days

DRUG

Digoxin

0.5mg dose

Sponsors & Collaborators

Principal Investigators

  • Rod Hepburn · AstraZeneca R&D, Charnwood, UK

  • Rainard Fuhr · Parexel

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00723424 on ClinicalTrials.gov